Elaxim™

For use in the reduction of mortality associated with acute myocardial infarction (AMI).
Analytical comparison with Innovator Product

Product Identity
- Peptide mapping
- Amino acid sequence coverage

Identical peptide map

Product purity
- SDS-PAGE

Size exclusion HPLC

Iso-electric focusing

Structural characterization
- Circular dichroism

In-vitro potency assay
Periodic Safety Update Report
Between 2007 - 2018, submitted PSURs to the DCGI, New Delhi includes data from 137157 patients.

Elaxim™ is approved for Acute Myocardial Infarction

We have affordable solution for:
- Cardiovascular diseases (CVDs), the number 1 cause of death globally, representing 31% of all deaths
- Over three quarters of CVD deaths which take place in low- and middle income countries

3rd Generation Thrombolytic
- Administered as a single bolus
- Dose: 0.2 mg/kg body weight
- Longer half life of 18-22 min
- 14 fold greater fibrin specificity than alteplase
- 80 times lesser susceptibility to PAI-1 than alteplase

Published efficacy and safety

The study conclusively establishes the safety and efficacy of indigenous TNK-tPA in Indian STEMI patients, including high-risk sub groups.

Pharmacological Reperfusion Therapy with Tenecteplase in 7,668 Indian Patients with ST Elevation Myocardial Infarction – A Real World Indian Experience
S.S. Iyengar1, T. Nair1, J.S. Hiremath1, Anjan Lal Dutta1, Uday JadHAV2, V.K. Kityal1, Dayananand Kambale1, Immanuel Sathyamurthy1, RK Jain1, M Subrahmanyan2, Prasant Kr Sahoo2

The findings of this study further reinforce the safety and efficacy of indigenous TNK-tPA in Indian patients presenting with STEMI, including high-risk sub groups.

In this retrospective, post-marketing assessment across India, 167 cardiologists from 102 centers across India participated. The study confirms that TNK-tPA is a safe and effective thrombolytic in Indian patients with STEMI. The major and minor bleeding complications are acceptable and comparable to available lytic drugs.
Pre-Hospital Thrombolysis (PHT)

- Reaching equipped hospital within the Golden Hour of 60-90 minutes from onset of heart attack is a challenge

- Any delay leads to progressive permanent damage to the heart

- PHT is an effort towards rapid diagnosis and treatment to save lives

- Mission Delhi was launched in April 2019 in collaboration with ICMR at AIIMS, New Delhi as a pilot study

Genova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to the development, production and commercialization of bio-therapeutics to address life-threatening diseases across various indications. Incorporating recombinant DNA technologies together with innovative bio-manufacturing practices, Genova has created cost effective solutions for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology and oncology markets.